CBD and the prostate: one human trial, and its limits
CBD has no recognised use for the prostate, whether for an enlarged prostate, prostatitis or cancer. Research consists of studies on cells and mice plus one human trial: 21 patients took 600 to 800 mg of pharmaceutical CBD a day, and the trial measured tolerability only. If you have urinary symptoms, the right step remains a medical consultation.
Key takeaways
- Shop-bought CBD products are not medicines, and none of them may claim any effect on the prostate.
- The single human trial published, in 2023, gave doses 300 to 400 times EFSA's provisional reference level.
- What happens in cells or mice does not allow conclusions about humans.
- Liver enzymes that CBD inhibits break down tamsulosin, a common treatment for an enlarged prostate.
- A sudden inability to pass urine is a medical emergency.
The short answer: CBD does not treat the prostate
Shop CBD is a hemp product with no medicine status and no authorisation for any prostate disease. Epidyolex, the only authorised cannabidiol medicine, is reserved for three rare forms of epilepsy; our article on CBD and epilepsy tells how it was approved.
No seller may present CBD as an answer to an enlarged prostate or to cancer. Regulation (EC) No 1924/2006 permits only authorised health claims on foods, and no authorised claim concerns CBD. MILDECA, the French drug policy agency, notes that a CBD product may claim a therapeutic effect only once it is authorised as a medicine.
The two diseases are separate. According to French national health insurance, an enlarged prostate, or benign prostatic hyperplasia, is the most common benign tumour in men. After 70, 37% of men have a form with urinary symptoms. Having an enlarged prostate does not raise the risk of prostate cancer.
What research has actually measured
Most studies look at cancer, and nearly all of them were done outside the human body. The most cited ones are summarised below.
| Study | Model | What was measured | What it allows us to conclude |
|---|---|---|---|
| O'Reilly et al., J Nat Prod, 2023 | Prostate cancer cells in culture | Less cell proliferation and invasion | A laboratory lead |
| Mudhish et al., ACS Pharmacol Transl Sci, 2024 | Mice carrying human tumours, 15 mg/kg a day | Slower tumour progression and recurrence | An animal result, to be confirmed in humans |
| Myint et al., Cancers, 2023 | 21 men, 600 to 800 mg a day for 90 days | Tolerability (primary endpoint), PSA as secondary endpoint | Tolerated dose; efficacy not assessed |
| Capasso et al., Urology, 2011 | Strips of rat and human bladder | Reduced bladder muscle contraction | An observation on isolated tissue |
In the 2023 Irish study, CBD reduced the proliferation and invasion of cancer cells in culture; the authors declare partial funding from a cannabis pharmaceutical company. The 2024 American study gave mice grafted with human tumour cells 15 mg of CBD per kilo a day. It reports slower progression and fewer recurrences over 30 and then 45 days. A result in mice still needs confirming in human trials before it means anything for a patient.
No human trial of CBD for an enlarged prostate has been published. The nearest work, from 2011, applied CBD to isolated bladder strips in a laboratory bath and saw their contractions decrease. The authors write that this needs confirming in a living organism.
The only human trial, read in detail
The University of Kentucky trial, published in 2023 in Cancers, followed 21 men whose PSA had started rising again after surgery or radiotherapy. For 90 days they took Epidyolex, the pharmaceutical CBD, at 600 and then 800 mg a day, with no placebo group.
Tolerability was the primary endpoint. Diarrhoea (55% of patients), nausea (25%) and fatigue (20%) were the most frequent side effects, all grade 1 or 2, that is mild to moderate. At 12 weeks, PSA was stable in 16 of the 18 patients assessed, partly down in one and up in another. With no control group, these figures cannot show any effect of CBD. The authors conclude only that 800 mg a day is a tolerated dose for future studies.
Set that dose against shop products. In February 2026, EFSA published a provisional safe level of about 2 mg of CBD a day for a 70 kg adult. The 600 to 800 mg given in the trial, under medical supervision, are 300 to 400 times that. Our article on what CBD clinical trials really show places the gap within the wider research.
Urinary symptoms: the signs that call for a consultation
French national health insurance lists the typical symptoms of an enlarged prostate: needing to urinate often, day and night, a weak or interrupted stream, a feeling that the bladder has not emptied, and leaks between visits to the toilet. Other conditions produce them too, since an infection, a bladder problem or a cancer can cause similar signs.
That is why a diagnosis matters. It involves a clinical examination and a urine test, sometimes an ultrasound or a urine flow measurement, and a PSA test when cancer is suspected. A sudden inability to urinate, with a full and painful bladder, is called acute urinary retention: an emergency that needs treatment at once.
The real risk behind this online search is putting off that consultation and trying a wellness product first. A CBD product cannot stand in for a diagnosis.
Prostate treatments and CBD: drug interactions
For an enlarged prostate, the main medicines are alpha-blockers (alfuzosin, doxazosin, tamsulosin, terazosin) and 5-alpha-reductase inhibitors (dutasteride, finasteride), as French national health insurance explains.
A review in Frontiers in Psychiatry reports that CBD inhibits several liver enzymes of the cytochrome P450 family, CYP3A4 and CYP2D6 among them. According to the professional leaflet for tamsulosin, these two enzymes metabolise it, and inhibiting them could increase exposure to it. The leaflet gives an order of magnitude: with ketoconazole, a strong CYP3A4 inhibitor, tamsulosin exposure is multiplied by 2.8. A known side effect of tamsulosin is a fall in blood pressure on standing up, which can cause fainting.
At the low doses of a shop product the interaction stays theoretical, and no one has measured it. If you take a prostate treatment or any other medicine, tell your doctor or pharmacist about CBD before using it, and bring the product with its certificate of analysis. The mechanism is explained in our article on CBD's grapefruit effect, and the precautions specific to later life in the one on CBD for older adults.
Frequently asked questions
No. No study supports it, and if you stop or replace a prescribed treatment without medical advice, you risk complications such as urinary retention.
Yes, mostly in the laboratory and in mice. The one human trial, in 2023, enrolled 21 patients and assessed how well high-dose CBD was tolerated; it did not assess efficacy.
Nobody knows, because no human trial has been published. The only data come from laboratory observations on isolated bladder strips.
No one has measured the risk, but it is plausible, since CBD inhibits two enzymes that break down tamsulosin. Check with your doctor or pharmacist before taking them together.
At 600 to 800 mg a day, mainly diarrhoea (55% of patients), nausea (25%) and fatigue (20%). Our article on CBD side effects details them by dose.
Written by the Phytogrammes team
Each journal article draws on cited primary sources: ANSM, EFSA, EUR-Lex and peer-reviewed publications. Product profiles are distinguished from documented laboratory results. Our approach.
Article published on . CBD is not a medicine.